Aim immunotech outlines recent progress across clinical development pipeline and provides business update

Company continues progress across ampligen® clinical development programs growing body of promising data demonstrates ampligen's potential to address multiple high-value indications ocala, fla., feb. 29, 2024 (globe newswire) -- aim immunotech inc. (nyse american: aim) (“aim” or the “company”) today highlighted recent accomplishments and provided a business outlook.
AIM Ratings Summary
AIM Quant Ranking